EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients

Cristina Martínez-Toledo, María Jiménez-Meseguer, Marta Molina-Alejandre, Virginia Calvo, Ana Collazo-Lorduy, Belén Sierra-Rodero, Mariola Blanco, Marta Martínez Cutillas, Ángeles Gil-González, Juan Manuel Gutiérrez-Escobedo, Sergio Vázquez Estévez, Natalia Fernández Núñez und 16 weitere

Pharmacological Research · 2026-06 · 228 · 108232

DOI: 10.1016/j.phrs.2026.108232 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pharmacological Research, 2026-06. Verfasst von Cristina Martínez-Toledo und 27 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadaho…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundacion Cientifica de la Asociacion Espanola Contra el Cancer, Horizon 2020 Framework Programme, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Agents, ImmunologicalHumansFemaleMaleMiddle AgedAgedBiomarkers, TumorPrognosisProgrammed Cell Death 1 ReceptorAged, 80 and overAdult

Stichwörter der Autor:innen

BiomarkerImmunotherapyNSCLCPembrolizumab

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBiomarkers, TumorProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • Medical Oncology, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
  • Pharmacy Unit, Hospital Universitario Severo Ochoa, Madrid, Spain; Universidad Alfonso X el Sabio (UAX), Villanueva de la Cañada, Madrid, Spain.
  • Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain.
  • Medical Oncology, Complejo Asistencial Universitario de León, León, Spain.
  • Medical Oncology, Hospital General Universitario Dr. Balmis, Alicante, Spain.
  • Universidad Alfonso X el Sabio (UAX), Villanueva de la Cañada, Madrid, Spain; Medical Oncology, Hospital Universitario Severo Ochoa, Madrid, Spain.

Förderung

  • Fundacion Cientifica de la Asociacion Espanola Contra el Cancer
  • Horizon 2020 Framework Programme
  • European Regional Development Fund
  • Gobierno de Espana Ministerio de Ciencia e Innovacion
  • European Commission
  • Albert Einstein Cancer Center
  • Santander Universities
  • Community of Madrid

Zitieren

APA

Martínez-Toledo, C., Jiménez-Meseguer, M., Molina-Alejandre, M., Calvo, V., Collazo-Lorduy, A., Sierra-Rodero, B., Blanco, M., Martínez Cutillas, M., Gil-González, Á., Gutiérrez-Escobedo, J. M., Vázquez Estévez, S., Fernández Núñez, N., Diz-Taín, P., Garrido Onecha, M. L., Martínez-Banaclocha, N., Peña, E., López Martín, A., Peña-Cabia, S., Sequero-López, S., …, & Provencio, M. (2026). Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients. Pharmacological Research, 228, 108232. https://doi.org/10.1016/j.phrs.2026.108232

Vancouver

Martínez-Toledo C, Jiménez-Meseguer M, Molina-Alejandre M, Calvo V, Collazo-Lorduy A, Sierra-Rodero B, et al. Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients. Pharmacological Research. 2026;228:108232. doi:10.1016/j.phrs.2026.108232

BibTeX
@article{MartnezToledo2026,
  author = {Martínez-Toledo, Cristina and Jiménez-Meseguer, María and Molina-Alejandre, Marta and Calvo, Virginia and Collazo-Lorduy, Ana and Sierra-Rodero, Belén and Blanco, Mariola and Martínez Cutillas, Marta and Gil-González, Ángeles and Gutiérrez-Escobedo, Juan Manuel and Vázquez Estévez, Sergio and Fernández Núñez, Natalia and Diz-Taín, Pilar and Garrido Onecha, María Luisa and Martínez-Banaclocha, Natividad and Peña, Elena and López Martín, Ana and Peña-Cabia, Silvia and Sequero-López, Silvia and Rogado, Jacobo and Sánchez-Hernández, Alfredo and Coves Sarto, Juan and Sala González, Ángeles and Mielgo, Xabier and García Marrero, Rosa D and García-Grande, Aránzazu and Cruz-Bermúdez, Alberto and Provencio, Mariano},
  title = {Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients},
  journal = {Pharmacological Research},
  year = {2026},
  volume = {228},
  pages = {108232},
  doi = {10.1016/j.phrs.2026.108232}
}
Kostenlos starten →